Results 161 to 170 of about 2,075,366 (204)

Unraveling the Role of Myocardial Inflammation in ATTR-CM: A Targetable Mechanism?

Circulation: Heart Failure
Aldostefano Porcari, Marianna Fontana, Mattia Riefolo   +2 more
openaire   +3 more sources

Prognostic Value of Radiotracer Uptake Quantification in Transthyretin Cardiac Amyloidosis (ATTR-CM)

Journal of Nuclear Cardiology
Vidya Nadig, Shreya Arvind, Abhishek. Singh, Sabeena Arora, Lane Duvall   +4 more
openaire   +2 more sources

Real-World Efficacy of Tafamidis in Korean ATTR-CM Patients: A Retrospective Observational Strain Analysis.

Korean Circulation Journal
BACKGROUND AND OBJECTIVES Transthyretin amyloid cardiomyopathy (ATTR-CM) is an under-recognized condition with high mortality if untreated. Tafamidis, a transthyretin stabilizer, reduces mortality and cardiovascular events in ATTR-CM, but data in Korean ...
Heayoung Shin, Kina Jeon, Darae Kim, D. Hong, M. Park, Sang Eun Yoon, S. Kim, Jung-Sun Kim, Kihyun Kim, Jinwon Choi   +9 more
semanticscholar   +1 more source

A deep learning model to score Tc-99m PYP uptake in patients with suspected ATTR-CM

European Heart Journal
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognised cause of heart failure (HF) in older adults, with its prevalence rising due to advancements in diagnostics.
D. Ou, C. Huang, Y. Chang, C. Ko, C. Chen, Y. Wu   +5 more
semanticscholar   +1 more source

Biomarker-based clinical evaluation in ATTR-CM: plasma fibroblast-growth-factor-23 assessment

European Heart Journal
Fibroblast Growth Factor 23 (FGF23) is a hormone involved in phosphate and mineral metabolism and has recently gained attention for its role in heart failure disease. Elevated FGF23 contributes to myocardial remodeling, left ventricular hypertrophy,
M. Eslami, N. Ermolaev, C. Kronberger, L. Schmid, M. Poledniczek, F. Alasti, A. Kammerlander, F. Duca, J. Kastner, J. Bergler-Klein, H. Haslacher, R. Badr Eslam   +11 more
semanticscholar   +1 more source

Acoramidis-Mediated Improvement in NT-proBNP at Month 30 Compared With Placebo in Patients With ATTR-CM: Results From the ATTRibute-CM Study

Journal of Nuclear Cardiology
A progressive rise in N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a prognostic marker of disease progression and is associated with an increased risk of mortality in patients with transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM ...
N. Sarswat, Ahmad Masri, Kunal Bhatt, Michele Emdin, Emer Joyce, Michel Khouri, Kai Vogtländer, J. Tamby, Adam Castaño, Jonathan C. Fox, Marianna Fontana, J. Gillmore, M. Hanna, P. García-Pavía   +13 more
semanticscholar   +1 more source

Abstract 4365531: Acoramidis Effect on All-Cause Mortality in Patients with p.V142I (V122I) Variant ATTR-CM: Findings From the ATTRibute-CM Study

Circulation
Introduction: Transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) arises from amyloidogenic aggregates of destabilized TTR protein in variant (ATTRv-CM) or acquired wild-type TTR (ATTRwt-CM). The p.V142I (V122I) variant is the most common pathogenic
K. Alexander, N. Sarswat, Margot Davis, S. Cuddy, Michelle M. Kittleson, Keyur B. Shah, Jan Griffin, Frederick L. Ruberg, Michel Khouri, Kunal Bhatt, D. Judge, Justin Grodin, Olakunle Akinboboye, Chris Chen, J. Tamby, Adam Castaño, J. Fox, Marianna Fontana, Julian D. Gillmore, M. Grogan, Scott D. Solomon   +20 more
semanticscholar   +1 more source

Outpatient diuretic intensification, NT-proBNP and eGFR as early markers of disease progression in patients with ATTR-CM: a validation study

European Heart Journal
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a complex heterogenous disease with non-linear progression. Criteria for disease progression based on natriuretic peptides, renal function and diuretic intensification have previously been ...
A. Sheikh, A. Porcari, A. Ioannou, J. Mansell, Y. Razvi, E. Zaro, M. Rauf, R. Patel, A. Martinez-Naharro, L. Venneri, C. Whelan, P. Hawkins, H. Lachmann, J. Gillmore, M. Fontana   +14 more
semanticscholar   +1 more source

Abstract 4368984: Telehealth Use Prior to Diagnosis Associated with Earlier Transthyretin Cardiac Amyloidosis (ATTR-CM) Disease Stage

Circulation
Introduction: Early diagnosis of transthyretin cardiac amyloidosis (ATTR-CM) is integral to the success of effective treatment. While prior studies have explored sociodemographic disparities in diagnostic delays, the impact of telehealth use on ATTR ...
Jenna Ghaddar, Gracia Fahed, Isaiah Jimenez, Nixuan Cai, Marina Adrianzen Fonseca, Hiroki Kitakata, Francois Haddad, Ronald Witteles, K. Alexander   +8 more
semanticscholar   +1 more source

Acoramidis Has a Beneficial Effect Compared With Placebo on Change From Baseline in NAC ATTR Stage at Month 30 in Patients With ATTR-CM: Results From the ATTRibute-CM Study

Journal of Nuclear Cardiology
The National Amyloidosis Centre (NAC) staging system for transthyretin amyloid cardiomyopathy (ATTR-CM) is used to classify patients into prognostic categories based on N-terminal pro-B-type natriuretic peptide (NT-proBNP) level and estimated ...
J. Gillmore, Martha Grogan, Timothy Sutton, Matthias Dupont, Nowell Fine, Kunal Bhatt, D. Delgado, Chris Chen, J. Tamby, S. Siddhanti, Jonathan C. Fox, Marianna Fontana   +11 more
semanticscholar   +1 more source